Case Reports in Gastroenterology
Published: October 2007
Simultaneous Onset of Ulcerative Colitis and Disseminated Pyoderma GangrenosumNeesse A. · Michl P. · Kunsch S. · Ellenrieder V. · Gress T.M. · Steinkamp M.Division of Gastroenterology and Endocrinology, IBD Centre, Philipps University Marburg, Marburg, Germany
Dr. Martin Steinkamp Division of Gastroenterology and Endocrinology, University Hospital Giessen and Marburg, Campus Marburg Philipps University Marburg, Baldinger Strasse DE–35043 Marburg (Germany) Tel. +49 6421 28 66460, Fax +49 6421 28 68922, E-Mail steinkam@med.uni-marburg.de |
|
Abstract
Pyoderma gangrenosum (PG) is an immune-mediated inflammatory skin condition representing one of the most distinct extraintestinal manifestations of inflammatory bowel disease (IBD). PG occurs independently from intestinal disease activity in about 1–2% of patients suffering from ulcerative colitis or Crohn’s disease and is characterized by chronic deep skin ulcers whose exact pathogenesis is still unknown. So far, patients with ulcerative colitis have only been reported to develop PG during the course of IBD but not at the initial manifestation of bowel symptoms. This is the first report demonstrating the simultaneous onset of ulcerative colitis and severe multifocal PG. In addition, we provide first evidence that infliximab may have a particularly powerful effect in early disseminated PG compared to late-onset PG, advocating an early application of this drug.
© 2007 S. Karger AG, Basel
Related Articles:
References
- Callen JP: Pyoderma gangrenosum. Lancet 1998;351:581–585.
- Nguyen KH, Miller JJ, Helm KF: Case reports and a review of the literature on ulcers mimicking pyoderma gangrenosum. Int J Dermatol 2003;42:84–94.
- Ross HJ, Moy LA, Kaplan R, Figlin RA: Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer 1991;68:441–443.
- Montoto S, Bosch F, Estrach T, Blade J, Nomdedeu B, Nontserrat E: Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia. Leuk Lymphoma 1998;30:199–202.
- Srebrnik A, Shachar E, Brenner S: Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. Cutis 2001;67:253–256.
- Langholz E: Ulcerative colitis: An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull 1999;46:400–415.
- Reichrath J, Bens G, Bonowitz A, Tilgen W: Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005;53:273–283.
- Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS: Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut 2006;55:505–509.
- Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR: Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98:1821–1826.
Article / Publication Details
Published online: October 12, 2007
Issue release date: July 2008
Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 0
eISSN: 1662-0631 (Online)
For additional information: https://www.karger.com/CRG
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
